The time to offer treatments for COVID-19
Binh Ngo, Paul E. Marik, Pierre Kory, Leland Shapiro, Raphael Thomadsen, José Iglesias, Stephen Ditmore, Marc Rendell, Joseph Varón, Michael P. Dubé, Neha Nanda, Gino In, Daniel G. Arkfeld, Preet M. Chaudhary, Vito M. Campese, Diana L. Hanna, David Sawcer, Glenn R. Ehresmann, David Peng, Miroslaw Smogorewski, April W. Armstrong, Rajkumar Dasgupta, Fred R. Sattler, Denise Brennan-Rieder, Cristina Mussini, Oriol Mitja, Vicente Soriano, Nicolas Peschanski, Gilles Hayem, Marco Confalonieri, Maria Carmela Piccirillo, António Ferreira, Iraldo Bello Rivero, Mika Turkia, Eivind H. Vinjevoll, Daniel O. Griffin, Ivan Fan‐Ngai Hung
Abstract
: Vaccines and antibodies are highly antigen specific, and new SARS-Cov-2 variants are appearing. We call on public health authorities to authorize treatments with known low-risk and possible benefit for outpatients in parallel with universal vaccination.